Latest Cetuximab Stories
AUSTIN, Texas, Aug.
Scientists at the inter-university Messerli Research Institute of the Vetmeduni Vienna, the Medical University of Vienna, and the University of Vienna have developed, for the first time, antibodies to treat cancer in dogs.
The new combination agent TAS-102 is able to improve overall survival compared to placebo in patients whose metastatic colorectal cancer is refractory to standard therapies.
For patients with KRAS wild-type untreated colorectal cancer, adding cetuximab or bevacizumab to combination chemotherapy offers equivalent survival.
LONDON, June 26, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:
In an aggressive disease known for poor response rates, researchers from The University of Texas MD Anderson Cancer Center found patients with advanced colorectal cancer responded well to a combination therapy of the drugs vermurafenib, cetuximab and irinotecan.
Study Shows Improved Survival Benefit in Panitumumab Arm THOUSAND OAKS, Calif., May 31, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced results from the Phase 2 PEAK study that reinforce
GERMANTOWN, Maryland and HILDEN, Germany, May 23, 2014 /PRNewswire/ -- - Clinically proven companion diagnostic gains U.S.
Vectibix is the First and Only Biologic to Offer Significant Survival Benefit as a First-Line Treatment with FOLFOX Chemotherapy for Patients with Wild-Type KRAS Metastatic Colorectal Cancer THOUSAND
Company also announces designation of Orphan Drug Status by FDA for VTX-2337 in Ovarian Cancer SEATTLE, April 17, 2014 /PRNewswire/ -- VentiRx Pharmaceuticals, Inc.
- A transitional zone between two communities containing the characteristic species of each.